Bosakitug (ATI-045)
Atopic Dermatitis
Phase 2Active (Enrollment Completed)
Key Facts
Indication
Atopic Dermatitis
Phase
Phase 2
Status
Active (Enrollment Completed)
Company
About Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapies for immuno-inflammatory diseases with high unmet need. The company's core strength is its proprietary KINect® platform, which enables rapid discovery of selective kinase inhibitors. Having divested its commercial assets, Aclaris now focuses entirely on advancing a promising pipeline, including candidates for rheumatoid arthritis, alopecia areata, and atopic dermatitis, aiming to address critical 'white spaces' in treatment paradigms.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |
| AX-158 | Artax Biopharma | Phase 2 |